摘要
目的:探讨罗格列酮对人腹膜微血管内皮细胞水孔蛋白1(AQP1)、血管内皮生长因子A(VEGFA)及环氧合酶2(COX-2)蛋白的影响。方法:(1)体外培养人腹膜微血管内皮细胞并分为4组;用倒置显微镜观察细胞形态学变化;(2)Western blotting检测细胞AQP1、VEGF-A和COX-2蛋白的表达;(3)real-time PCR检测细胞AQP1、VEGF-A及COX-2 mRNA的表达。结果:罗格列酮可促进人腹膜微血管内皮细胞增殖,上调AQP1蛋白及基因的表达(P<0.05),下调VEGF-A和COX-2蛋白和mRNA的表达,过氧化物酶体增殖物激活受体γ(PPAR-γ)拮抗剂GW9662可部分抑制罗格列酮上调的AQP1表达(P<0.05),但对VEGF-A及COX-2表达无明显影响(P>0.05)。结论:罗格列酮能够上调腹膜微血管内皮细胞AQP1的表达,下调VEGF-A及COX-2的表达,这可能与罗格列酮增加腹膜水转运、减轻腹膜纤维化有关。
AIM:To investigate the effect of rosiglitazone on the expression of aquaporin-1 (AQP1), vascular endothelial growth factor-A ( VEGF-A ) and cyclooxygenase-2 ( COX-2 ) in human peritoneal microvascular endothelial cells.METHODS: Cultured peritoneal microvascular endothelial cells were divided into 4 groups.The morphological changes of the cells were observed under inverted microscope .The protein expression of AQP1, VEGF-A and COX-2 in hu-man peritoneal microvascular endothelial cells was determined by Western blotting .The mRNA expression of AQP1, VEGF-A and COX-2 in the cells was measured by real-time PCR.RESULTS:Rosiglitazone stimulated the proliferation of the cells.Rosiglitazone up-regulated the expression of AQP1, and down-regulated the expression of VEGF-2 and COX-2 at mRNA and protein levels in the cells .The PPAR-γantagonist GW9662 partly inhibited the up-regulation of AQP1 expres-sion by rosiglitazone (P〈0.05), but had no obvious effect on the expression of VEGF-A and COX-2 (P〉0.05).CON-CLUSION:Rosiglitazone up-regulates the expression of AQP 1 and down-regulates the expression of VEGF-A and COX-2 in human peritoneal microvascular endothelial cells , thus promoting water transportation and attenuating peritoneal fibrosis during peritoneal dialysis .
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2015年第1期44-48,共5页
Chinese Journal of Pathophysiology
基金
浙江省自然科学基金资助项目(No.Y13H050021)
宁波市卫生局项目(No.2010A18)